HealthPhoto: Hindu HealthIndia Rejects Patent for Shorter Drug-Resistant TB Treatment
The Indian Patent Office rejected a patent application by the U.S.-based Global Alliance for TB Drug Development for BPaL, a six-month all-oral regimen combining bedaquiline, pretomanid, and linezolid. Recommended by WHO for certain drug-resistant tuberculosis patients, BPaL offers a shorter, more effective treatment compared to older regimens lasting 18–24 months. The decision highlights ongoing debates on intellectual property and access to medicines.
Hindu Health·


